Skip to main content

The independent source for health policy research, polling, and news.

Subscribe Follow Us Donate
  • Trump 2.0

    Trump 2.0

    • Agency Watch
    • State Watch
    • Rural Health Payout
  • Public Health

    Public Health

    • Vaccines
    • CDC & Disease
    • Environmental Health
    All Public Health
  • Audio Reports

    Audio Reports

    • What the Health?
    • Healthcare Helpline
    • KFF Health News Minute
    • An Arm and a Leg
    • Health Hub
    • HealthQ
    • Silence in Sikeston
    • Epidemic
    All Audio
  • Special Reports

    Special Reports

    • Bill Of The Month
    • Common Ground
    • Diagnosis: Debt
    • The Body Shops
    • Priced Out
    • Guns, Race, and Profit
    • Broken Rehab
    • Dead Zone
    • Denied
    • Opioid Settlement Tracking
    • Eleven Minutes
    All Special Reports
  • More Topics

    More Topics

    • Elections
    • Healthcare Costs
    • Insurance
    • Prescription Drugs
    • Health Industry
    • Immigration
    • Reproductive Health
    • Technology
    • Rural Health
    • Race and Health
    • Aging
    • Mental Health
    • Affordable Care Act
    • Medicare
    • Medicaid
    • Children’s Health
    All Topics

  • Medicare Advantage Billing Probe
  • School Vaccine Mandates
  • Weight Loss Drugs Coverage
  • Opioid Settlement Money
  • Abortion Pill Access

Morning Briefing

Summaries of health policy coverage from major news organizations

  • Email

Monday, Jul 15 2019

Full Issue

Democrats Urge Trump To Remove Language About Biologics In Trade Agreement

The lawmakers say the pending language in the U.S.-Mexico-Canada agreement “would hinder Congress from taking action to increase competition and enhance patient access to more affordable medicines.”

Stat: Lawmakers Urge Trump Administration To Alter Trade Deal Or Americans Will Pay More For Drugs

More than 100 Democratic members of Congress urged the Trump administration to remove pending language from the U.S.-Mexico-Canada Agreement trade agreement that would lock the U.S into at least 10 years of marketing exclusivity for biologics, a move they argue will hurt taxpayers and patients. (Silverman, 7/12)

In other pharmaceutical news —

Reuters: Democrats Take Aim As Trump Abandons Drug Pricing Plan

Democrats see U.S. President Donald Trump becoming increasingly vulnerable to criticism about healthcare costs after the administration's decision to scrap a proposal to lower drug prices, and 2020 White House candidates are rushing to seize the spotlight on the issue. The debate over the future of the American healthcare system has become a focal point of the Democratic presidential nominating contest. As Trump has failed to make strides to remedy the problem, Democrats are becoming more vocal. (Gibson, 7/13)

This is part of the Morning Briefing, a summary of health policy coverage from major news organizations. Sign up for an email subscription.
Newsletter icon

Sign Up For Our Newsletter

Stay informed by signing up for the Morning Briefing and other emails:

Recent Morning Briefings

  • Today, July 21
  • Monday, July 20
  • Friday, July 17
  • Thursday, July 16
  • Wednesday, July 15
  • Tuesday, July 14
More Morning Briefings
RSS Feeds
  • Podcasts
  • Special Reports
  • Morning Briefing
  • About Us
  • Donate
  • Staff
  • Republish Our Content
  • Contact Us

Follow Us

  • Instagram
  • YouTube
  • LinkedIn
  • Facebook
  • X
  • Bluesky
  • TikTok
  • RSS

Sign up for emails

Join our email list for regular updates based on your personal preferences.

Sign up
  • Editorial Policy
  • Privacy Policy

© 2026 KFF